Biotech Values

[NP1986]

I don't mean mean head-to-head in the first line setting, but rather in the second line setting. If the contention is that second generation TKIs and ponatinib will struggle to make inroads into the first line market once Gleevec goes generic, then the second line market is perhaps a more realistic target for Ariad.

Some posters have commented that ponatinib will become the de facto second line therapy of choice; however, I don't see it as a given based solely on the results of PACE.

As for getting a foot in the door in the front line setting, I don't think Ariad has much time to do that. It took Sprycel and Tasigna three years to get a first line indication, after initiating their respective first line phase III trials.